|
| Tuesday, December 20, 2016 |
|
|
Anticancer Agent Treakisym Approved in Japan for Additional Indication as First-Line Treatment for Low-Grade B-Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma |
| Eisai Co., Ltd. announced today that the anticancer agent TREAKISYM (generic name: bendamustine hydrochloride) has been approved in Japan for an additional indication as first-line treatment for low-grade B-cell non-Hodgkin's lymphoma and mantle cell lymphoma (MCL). more info >> |
|
| Wednesday, November 30, 2016 |
|
|
エーザイ、第39回サンアントニオ乳がんシンポジウムでエリブリンに関する最新データを発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、2016年12月6日から10日まで米国サンアントニオで開催される「第39回サンアントニオ乳がんシンポジウム（San Antonio Breast Cancer Symposium： SABCS2016）」において、当社が創製したエリブリンメシル酸塩（ハリコンドリン系微小管ダイナミクス阻害剤、製品名：「ハラヴェン(R)」）に関する最新の臨床試験データを発表することをお知らせします。 more info >> |
|
|
エーザイ、第70回米国てんかん学会議にてペランパネルおよびルフィナミドに関する最新データを発表 |
| エーザイ株式会社は、2016年12月2日から6日まで米国ヒューストンで開催される「第70回米国てんかん学会議（American Epilepsy Society：AES2016）」において、抗てんかん剤ペランパネル（製品名「フィコンパ(R)」、英名「Fycompa(R)」）、およびルフィナミド（製品名「イノベロン(R)」、米国製品名「Banzel(R)」）に関する最新データを発表しますのでお知らせします。 more info >> |
|
| Friday, November 18, 2016 |
|
|
エーザイ、早期アルツハイマー病を対象としたBACE阻害剤「E2609」の開発について |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、自社創製の経口BACE（βサイト切断酵素）阻害剤「E2609」の開発について、米国医薬食品局（FDA）よりファストトラック指定（Fast Track designation）を受領しましたのでお知らせします。 more info >> |
|
|
U.S. FDA Grants Fast Track Designation for the Development of Eisai's Bace Inhibitor E2609 for Early Alzheimer's Disease |
| Eisai Co., Ltd. announced today that the U.S. FDA has granted Fast Track designation for the development of the beta secretase cleaving enzyme (BACE) inhibitor E2609 which was discovered by Eisai and is being jointly developed by Eisai and Biogen Inc. more info >> |
|
| Friday, March 29, 2024 |
|
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 |
| Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), the dual orexin receptor antagonist discovered by Eisai, has been honored with The Pharmaceutical Society of Japan (PSJ) Award for Drug Research and Development 2024 by the PSJ. more info >> |
|
| Thursday, March 21, 2024 |
|
|
Lifenet and Eisai Co-Develop Dementia Insurance "be" |
| LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia and mild cognitive impairment (hereafter, "MCI") as one of the initiatives under the capital and business alliance agreement concluded in August 2022 for collaboration in dementia and other areas. more info >> |
|
|
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace |
| Eisai Co., Ltd. announced today that it has been selected for the first time by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as one of the Nadeshiko Brand 2024, as a listed company excelling in the promotion of women in the workplace. more info >> |
|
| Wednesday, March 6, 2024 |
|
|
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC to support C2N's efforts to expand the availability, accessibility, affordability and utilization of blood-based tests for the diagnosis of Alzheimer's disease (AD) in the U.S. more info >> |
|
|
エーザイ、早期アルツハイマー病の診断の簡便化を支援するためC2N Diagnostics LLCに出資 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、当社米国子会社エーザイ・インクが、C2N Diagnostics LLC（本社：米国ミズーリ州セントルイス 以下 C2N）による米国におけるアルツハイマー病（AD）の血液診断の実用化ならびに、アクセス、アフォーダビリティ、および利用の拡大に向けた取り組みを支援するため、同社に最大15百万米ドルの出資を決定したことをお知らせします。 more info >> |
|
|
|
|
